A new series of estrogen receptor ligands based on a 6-hydroxy-tetrahydroquinoline scaffold is described, in addition to their binding affinity and functional activity in MCF-7 cells. Several 1,2-disubstituted tetrahydroquinolines bearing a basic side chain were shown to be high affinity ligands and antagonists in the MCF-7 proliferation assay. Compounds lacking the basic side chain were agonists in the MCF-7 assay. (C) 2003 Elsevier Science Ltd. All rights reserved.
A new series of estrogen receptor ligands based on a 6-hydroxy-tetrahydroquinoline scaffold is described, in addition to their binding affinity and functional activity in MCF-7 cells. Several 1,2-disubstituted tetrahydroquinolines bearing a basic side chain were shown to be high affinity ligands and antagonists in the MCF-7 proliferation assay. Compounds lacking the basic side chain were agonists in the MCF-7 assay. (C) 2003 Elsevier Science Ltd. All rights reserved.
2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
申请人:——
公开号:US20040215018A1
公开(公告)日:2004-10-28
The current invention provides novel 2-substituted 1,2,3,4-tetrahydroquinolin-6-ols and derivatives thereof of the formula (I) (A); pharmaceutical compositions thereof, optionally in combination with estrogen or progestin; methods for inhibiting a disease associated with estrogen deprivation; and methods for inhibiting a disease associated with an aberrant physiological response to endogenous estrogen.
1
2-SUBSTITUTED 1,2,3,4-TETRAHYDROQUINOLINES AND DERIVATIVES THEREOF, COMPOSITIONS AND METHODS
申请人:ELI LILLY AND COMPANY
公开号:EP1395563A1
公开(公告)日:2004-03-10
US7056931B2
申请人:——
公开号:US7056931B2
公开(公告)日:2006-06-06
[EN] 2-SUBSTITUTED 1,2,3,4-TETRAHYDROQUINOLINES AND DERIVATIVES THEREOF, COMPOSITIONS AND METHODS<br/>[FR] 1,2,3,4-TETRAHYDROQUINOLINE 2-SUBSTITUEES ET LEURS DERIVES, AINSI QUE LEURS COMPOSITION ET LEURS PROCEDES
申请人:LILLY CO ELI
公开号:WO2002094788A1
公开(公告)日:2002-11-28
The current invention provides novel 2-substituted 1,2,3,4-tetrahydroquinolin-6-ols and derivatives thereof of the formula (I) (A); pharmaceutical compositions thereof, optionally in combination with estrogen or progestin; methods for inhibiting a disease associated with estrogen deprivation; and methods for inhibiting a disease associated with an aberrant physiological response to endogenous estrogen.